Blood bags and storage containers
Technology class
Blood bags and storage containers
Blood collection and storage bags, containers, and systems with specialized materials or gas permeability for blood component preservation
Blood bags and storage containers are specialized polymer-based systems engineered to maintain viability and function of blood components throughout collection, processing, storage, and transfusion. These enabling technologies underpin every other blood product mechanism in the hemorrhagic shock landscape, as the container's material properties, gas permeability, anticoagulant-preservative formulation, and port design directly determine achievable shelf life, component quality, and field deployability.
Effective holders is the inverse of the HHI (1 ÷ HHI): a measure of how concentrated patent ownership is in this class.
Technology mechanism
Modern blood bag systems employ multi-layer polymer constructions, typically combining polyvinyl chloride plasticized with di-2-ethylhexyl phthalate or alternative plasticizers such as butyryl-n-trihexyl-citrate or di-isononyl-cyclohexane-1,2-dicarboxylate for red cell storage, with polyolefin or fluoropolymer layers for platelet containers requiring high oxygen permeability. Red cell storage bags maintain anaerobic or low-oxygen environments to minimize oxidative lesion accumulation, with newer designs incorporating oxygen-scavenging materials or reduced gas permeability barriers to extend storage beyond the standard 42-day limit in additive solutions. Platelet storage containers conversely require oxygen transmission rates exceeding 2,000 mL per square meter per day at atmospheric pressure to support aerobic metabolism during 5-7 day room temperature storage with continuous agitation. Integrated satellite bag configurations enable closed-system processing where whole blood collection into a primary bag containing anticoagulant-preservative solution such as citrate-phosphate-dextrose connects via sterile tubing to secondary bags for component separation by centrifugation, with additive solution bags providing AS-1, AS-3, AS-5, or AS-7 formulations that extend red cell storage. Port designs incorporate spike ports for additive solution addition, needle-free sampling sites, and leukoreduction filter integration points. Container volumes range from 50 mL pediatric bags through standard 450-500 mL collection units to 600 mL extended-draw configurations. Specialized designs for cryopreservation applications employ materials rated for minus 80 degrees Celsius storage without embrittlement, while bags intended for pathogen reduction integration include ports compatible with illumination devices and photosensitizer addition. Transfer bag systems with multiple satellite containers enable plasma separation, cryoprecipitate preparation, and platelet pooling within closed systems that maintain sterility and extend component dating.
Operational footprint
Blood bag systems require minimal specialized infrastructure for basic use, functioning with standard phlebotomy equipment and gravity or centrifuge-based processing. Training requirements scale with processing complexity, from straightforward whole blood collection requiring basic phlebotomy competency through component preparation demanding centrifuge operation expertise and quality control monitoring. Adoption is essentially universal across blood banking operations globally, with annual consumption exceeding 100 million units worldwide. Environmental tolerance varies by intended application, with standard PVC bags maintaining integrity from 4 to 37 degrees Celsius during normal handling, while cryopreservation-rated containers withstand thermal cycling between minus 80 degrees and room temperature. Field deployment for pre-hospital and remote settings requires consideration of bag durability during transport, compatibility with rapid infusion devices and blood warmers, and port accessibility in moving vehicles. Weight and volume footprint is minimal, with empty bag systems weighing under 100 grams, though filled units add approximately 500 grams per standard collection. Integration with portable refrigeration systems, pathogen reduction platforms, and leukoreduction filters requires matching port configurations and tubing diameters across manufacturers.
Maturity signals
Blood bag technology represents a mature commercial market with established regulatory pathways and decades of clinical validation, though the patent landscape reveals continued innovation in materials science and functional design. The mechanism's patent cluster of 184 filings across 10 unique assignees demonstrates concentrated activity among major transfusion medicine manufacturers, with Terumo Corporation holding the dominant position followed by Pall Corporation and legacy Bayer operations. This assignee concentration reflects the capital-intensive nature of polymer manufacturing and the regulatory burden of demonstrating biocompatibility and component quality maintenance. Patent activity focuses on gas permeability optimization, plasticizer alternatives addressing phthalate concerns, integration points for emerging technologies such as pathogen reduction and oxygen depletion systems, and designs enabling extended storage claims. Despite this being a foundational enabling technology for hemorrhagic shock resuscitation, no commercial players specific to this mechanism appeared in the roster for this report, indicating that blood bag manufacturers operate primarily within the broader transfusion medicine supply chain rather than as hemorrhage-focused specialists. The technology readiness level is 9 with widespread commercial availability, though innovation continues at the materials and integration interface level.
Challenges
Plasticizer leaching remains a persistent concern, with di-2-ethylhexyl phthalate migration into stored red cells reaching concentrations of 50-80 milligrams per unit, prompting regulatory scrutiny and driving development of alternative plasticizers that maintain flexibility without endocrine-disrupting potential. Material compatibility constraints limit integration options, as bags optimized for red cell storage with low oxygen permeability are unsuitable for platelets requiring aerobic metabolism, necessitating separate container inventories and complicating whole blood programs. Cold chain maintenance during transport and field deployment challenges container integrity, with freeze-thaw cycles causing microcracking in standard PVC formulations and temperature excursions accelerating plasticizer migration. Port standardization across manufacturers remains incomplete, creating interoperability barriers when connecting bags to infusion devices, warmers, or pathogen reduction systems from different suppliers. Regulatory approval timelines for novel materials or designs extend 2-4 years given requirements for biocompatibility testing, accelerated aging studies, and clinical validation of component quality, slowing adoption of innovations that could extend shelf life or improve field durability. Unlike dried plasma systems in M1 that eliminate cold chain requirements entirely, or hypoxic storage approaches in M6 that actively modify the storage environment, conventional blood bag technology remains fundamentally constrained by passive material properties that cannot fully arrest storage lesion progression.